AstraZeneca is not responsible for the privacy policy of any third party websites. The combination represents a significant step in AstraZeneca's strategic and financial-growth plans. The acquisition is expected to improve the combined Group’s profitability, with the core operating margin significantly enhanced in the short term, and with continued expansion thereafter. Elliott did not immediately respond to a request for comment. It has been prepared solely for the proposed acquisition referred to in this announcement. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP and should be reviewed in conjunction with the relevant GAAP financial measures. The boards of directors of both Alexion and AstraZeneca have unanimously approved the proposed acquisition and resolved to recommend that their respective shareholders vote in favour of it. More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases. Alexion shareholders will receive $60 in cash plus 2.1243 AstraZeneca American depositary receipts for each share they own, according to a joint statement […] AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. ASTRAZENECA has agreed to buy US biotech firm Alexion for US$39bn in a move that will expand its foothold in immunology treatments. (vii) The percentage of the share capital of the combined Group that will be owned by Alexion Shareholders is calculated by dividing the number of New AstraZeneca Shares to be issued pursuant to the terms of the acquisition referred to in paragraph (vi) above by the issued share capital of the combined Group (as set out in paragraph (vi) above) and multiplying the resulting sum by 100 to product a percentage. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Rare diseases is a high-growth therapy area with rapid innovation and significant unmet medical need. The presentation will be available at astrazeneca.com before the call takes place, and replay details after the call. Pharmaceutical News - Health Industry Hub - AstraZeneca buys Alexion for $39B in 2020’s biggest pharma deal. Forward-looking statements may and often do differ materially from actual results. The acquisition is a Class 1 transaction for AstraZeneca and as such, will require the approval of its shareholders to comply with the UK Listing Rules. Economic, competitive, governmental, technological and other factors that may affect AstraZeneca's and Alexion's operations are discussed in the section entitled "Risk Factors," in each of AstraZeneca's Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion's Annual Report on Form 10-K for the year ended 31 December 2019, in each case as amended by any subsequent filings made with the SEC. A precursor cash call, on a much smaller scale, was a $3.5 billion issue last year to fund the purchase of rights to cancer drug Enhertu from Daiichi Sankyo. None of the Responsible Persons, AstraZeneca or its affiliated companies have reviewed and none of them is responsible for, or accepts any liability in respect of, any information on any other website that may be linked to this website by a third party. EvaluatePharma, World Preview 2020, Outlook to 2026. Enhanced revenue growth, operating margin and cash-flow generation. The acquisition is expected to realise recurring run-rate pre-tax synergies of c.$500m per year from the combined Group, generated from commercial and manufacturing efficiencies as well as savings in central costs, with full run-rate expected to be achieved by end of the third year following completion of the acquisition. AstraZeneca reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit this area of the website. AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs. The combined company is expected to deliver double-digit average annual revenue growth through 2025. This notice shall be governed by, and interpreted in accordance with, English law. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021, and upon completion, Alexion shareholders will own c.15% of the combined company. Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. As a leader in rare diseases for more than 25 years, Alexion has developed and commercialises two approved complement inhibitors to treat patients with PNH and atypical haemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalised myasthenia gravis and neuromyelitis optica spectrum disorder. Certain figures contained in this announcement, including financial information, have been subject to rounding adjustments. Confirmation of Understanding and Acceptance of Disclaimer, AstraZeneca to acquire Alexion, accelerating the Company's strategic and financial development. AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and … Pharmaceutical giant AstraZeneca has said it is buying a US drug company in a deal worth 39 billion US dollars (£29 billion). I am incredibly proud of what our organisation has accomplished and am grateful to our employees for their contributions. Company Secretary To realise the total synergies, AstraZeneca expects to incur one-time cash costs of c.$650m, during the first three years following completion. AstraZeneca is buying Alexion Pharmaceuticals for $39 billion in cash and stock, or $175 a share, in one of the year’s largest drug mergers. AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca PLC. Based on a reference average ADR price of $54.14, that implies a total price of $175 per share. Alexion has exhibited skilful commercial execution in building its 'blockbuster' C5 franchise. This announcement is not a prospectus for the purposes of the UK Prospectus Regulation Rules or the EU Prospectus Regulation. If you would like to view this area of the website, please read this notice carefully. In connection with the Transaction, AstraZeneca intends to file a registration statement on Form F-4 with the United States Securities and Exchange Commission (SEC), which will include a document that serves as a prospectus of AstraZeneca and a proxy statement of Alexion, Alexion intends to file a proxy statement with the SEC and each party will file other documents regarding the proposed transaction with the SEC. Goldman Sachs International, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, and Goldman Sachs Bank USA, which is authorised and regulated by the Board of Governors of the Federal Reserve System (Federal Reserve Board), the FDIC and the New York State Department of Financial Services, are each acting exclusively for AstraZeneca and no one else in connection with the transaction and the matters referred to in this document and will not regard any other person as a client in relation to the matters set out in this document and will not be responsible to anyone other than AstraZeneca for providing the protections afforded to their respective clients, nor for providing advice in relation to the transaction or any other matter referred to in this document. THE DOCUMENTS IN THIS AREA OF THE WEBSITE MAY NOT BE DOWNLOADED, FORWARDED, TRANSMITTED OR SHARED WITH ANY OTHER PERSON EITHER IN WHOLE OR IN PART WHERE TO DO SO WOULD OR MAY CONSTITUTE A BREACH OF ANY APPLICABLE LOCAL LAWS OR REGULATIONS. The dividend policy remains unchanged with a commitment to a progressive dividend policy; dividend cover is expected to be materially enhanced as a result of the acquisition. Investors and security holders of Alexion are urged to carefully read the entire registration statement and proxy statement/prospectus or proxy statement and other relevant documents filed with the SEC when they become available because they will contain important information. In connection with such matters, Morgan Stanley and J.P. Morgan Cazenove, each of their respective affiliates and their respective directors, officers, employees and agents will not regard any other person as a client, nor will they be responsible to any other person for providing the protections afforded to their respective clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein. I have read this warning and will not be using any of the contained product information for clinical purposes. (ii) Any references to the issued and to be issued ordinary share capital of Alexion are based on: • the 218,720,567 Alexion Shares referred to in paragraph (i) above; and. The initial bridge financing facility is intended to cover the financing of the cash portion of the acquisition consideration and associated acquisition costs and to refinance the existing term loan and revolving credit facilities of Alexion. Investors and security holders will be able to obtain the registration statement and the proxy statement/prospectus or the proxy statement free of charge from the SEC's website or from AstraZeneca or Alexion as described in the paragraphs below. It plays a crucial role in many inflammatory and autoimmune diseases across multiple therapy areas, including haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Hedge fund and activist investor Elliott Management has urged Alexion to seek a buyer and in May spoke out publicly. AstraZeneca remains committed to maintaining a strong investment-grade credit rating. Rather, Alexion brings AstraZeneca to the front of rare disease drugmaking — a field that it has shown little interest in until now. In contrast, AstraZeneca's capabilities in genomics, precision medicine and oligonucleotides can be leveraged to develop medicines targeting less-frequent diseases. The success of the franchise is demonstrated by the effective transition of over 70% of PNH patients from Soliris to Ultomiris in less than two years of launch in its key markets, including the US, Japan and Germany, as well as the strong pipeline of additional indications for Ultomiris. Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. AstraZeneca hopes that an improved version of Soliris called Ultomiris has an even larger market potential. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients. Alexion shares closed at around $121 apiece on Friday. In due course, AstraZeneca intends to refinance the initial bridge-financing facility through a combination of new medium-term bank loan facilities, debt-capital market issuances and business cash flows. If they elect, Alexion shareholders may receive their allocation of AstraZeneca ADSs in the form of a corresponding number of ordinary shares of AstraZeneca in addition to the cash consideration. Click here for available international numbers. In addition, Alexion is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, FcRn antibody for rare IgG-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. A circular is expected to be published by AstraZeneca in connection with the proposed acquisition in due course. AstraZeneca will pay $60 in cash and 2.1243 AstraZeneca American Depositary Shares for each Alexion share held. Forward-looking statements may and often do differ materially from actual results. Over 7,000 rare diseases are known today, and only c.5% have US Food and Drug Administration-approved treatments.1 The global rare disease market is forecasted to grow by a low double digit percentage in the future.2. I represent and warrant to AstraZeneca that I intend to access this area of the website for information purposes only, that I have read and understood this notice and that I understand that it may affect my rights or responsibilities. The British firm said the boards of both companies had approved the deal, which is expected to close in the third quarter of 2021. AstraZeneca plc (NASDAQ: AZN)has announced it will buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a Boston-based drugmaker, for $39 billion. AstraZeneca intends to build on its geographical footprint and extensive emerging markets presence to accelerate the worldwide expansion of Alexion's portfolio. It also expects around $650 million in one-time cash costs during the three years following completion. … Please refer to your approved national product label (SmPC) for current product information. All Alexion financial information in this announcement is presented following US GAAP and may be different in the Circular, which will be prepared under IFRS and AstraZeneca's accounting policies. In particular, you should not forward or transmit the announcements, information or documents contained therein to Canada, Australia, Japan or South Africa or to any other jurisdiction where it would be unlawful to do so. • 6,202,972 Alexion Shares which may be issued on or after the date of this announcement to satisfy the exercise of stock options and restricted and performance stock awards outstanding under the Alexion Share Plans, estimated based on the total consideration of $175 per Alexion share and calculated in accordance with the Treasury Stock Method. This deal will give AstraZeneca Soliris and its … AstraZeneca said it expected the deal to immediately boost core earnings and to deliver pretax synergy gains of around $500 million per year. To the fullest extent permitted by applicable law, each of Evercore, Centerview Partners and Ondra and each of their respective affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this announcement or any statement contained therein. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. In particular, the information contained in this website does not constitute an offer to sell or otherwise dispose of or any invitation or solicitation of any offer to purchase or subscribe for any securities pursuant to the Transaction or otherwise in any jurisdiction in which such offer or solicitation is unlawful. AstraZeneca to buy Alexion for $39 billion to expand in immunology FRANKFURT (Reuters) -Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in … Save as required by law or regulation, AstraZeneca and Alexion disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements in this announcement that may occur due to any change in their expectations or to reflect events or circumstances after the date of this announcement. Electronic versions of these materials are not directed at or accessible by persons resident in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. Alexion achieved impressive revenue growth over the last few years, with revenues of $5.0bn in 2019 (21% year-on-year growth). AstraZeneca is splashing out $39 billion to buy Alexion in a cash-and-stock deal, the British pharma revealed Saturday. The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its COVID-19 vaccine could be 90% effective, potentially slowing its rollout, and as a rival shot from Pfizer was launched in Britain and approved for use in the United States. Alexion’s best-selling drug is Soliris, used against a range of rare immune-disorders including paroxysmal nocturnal hemoglobinuria (PNH), which causes anaemia and blood clots, and whose revenue rose 3.6% in the first nine months to $3 billion. FRANKFURT (Reuters) -Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs. Forward-looking statements speak only as of the date they are made and cannot be relied upon as a guide to future performance. Immediately earnings-accretive and value-enhancing acquisition, in line with stated capital-allocation priorities. Free copies of these documents may be obtained as described in the paragraphs above. The acquisition strengthens AstraZeneca's industry-leading growth, underpinned by its broad portfolio of medicines, which will enable the new company to bring innovative medicines to a broad range of healthcare practitioners in primary, speciality and highly specialised care. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "envisages", "plans", "projects", "anticipates", "targets", "aims", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions and include, but are not limited to the ability of the parties to consummate the proposed acquisition on a timely basis or at all, the ability of the parties to satisfy the conditions precedent to consummation of the proposed acquisition, including the ability to secure the required regulatory approvals on the terms expected, at all or in a timely manner, the ability of AstraZeneca to successfully integrate Alexion's operations, and the ability of AstraZeneca to implement its plans, forecasts and other expectations with respect to Alexion's business after the completion of the proposed acquisition and realise expected synergies. The combined company will have recurring run-rate pre-tax synergies of roughly $500 million. I certify that I am not (nor do I act on behalf of someone who is) resident in any country that renders the accessing of this area of the website or parts thereof illegal, including, without limitation, Canada, Australia, Japan or South Africa. AstraZeneca [AZN] said it agreed to buy Boston-based Alexion Pharmaceuticals Inc. [ALXN] for $39 billion in cash and stock, a move that would bolster the British drug giant’s footprint in rare diseases. AstraZeneca expects to generate significant value from the acquisition by extending Alexion's commercial reach through leveraging AstraZeneca’s global presence and accelerating the development of Alexion's pipeline. Sweden: +46 8 5052 0017 Neither Evercore, Centerview Partners nor Ondra, nor any of their respective subsidiaries, holding companies, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client in connection with the transaction or any statement contained herein or otherwise. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM PART OF, AND SHOULD NOT BE CONSTRUED AS, ANY OFFER, INVITATION OR RECOMMENDATION TO PURCHASE, SELL OR SUBSCRIBE FOR ANY SECURITIES IN ANY JURISDICTION AND NEITHER THE ISSUE OF THE INFORMATION NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF OR BE RELIED UPON IN CONNECTION WITH, OR ACT AS AN INDUCEMENT TO ENTER INTO, ANY INVESTMENT ACTIVITY. Consequently, there can be no certainty that the completion of the proposed acquisition will be forthcoming. Subject to the satisfaction of the closing conditions to the proposed acquisition, the companies expect the acquisition to close in Q3 2021. I agree that I will not forward, transfer or distribute (by any means including by electronic transmission) any documents included in this area of the website either in whole or in part to any person in Canada, Australia, Japan or South Africa or any other jurisdiction where such distribution may be restricted by applicable law or regulation. In addition, the contents of this area of the website may be amended at any time in whole or in part at the sole discretion of AstraZeneca. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this announcement may not conform precisely with the total figure given. Soriot also told reporters the deal was the result of exclusive talks and no competitive bidder was involved. The two companies have been on converging paths, AstraZeneca expanding its presence from primary to speciality care, whereas Alexion has been progressing from ultra-orphan to orphan and speciality conditions. Cambridge-based AstraZeneca, which is developing a coronavirus vaccine with the University of Oxford, said on Saturday the acquisition of Alexion Pharmaceuticals had been given the green-light by directors, but still needs shareholder and regulatory approval. The deal would see AstraZeneca diversifying from its cancer business for a major investment in rare-disease and immunology drugs. ", Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. Industry-leading revenue growth; enhanced geographical presence and broad coverage across primary, specialised and highly specialised care. 1. In fact, about three years ago AstraZeneca spun out several rare disease drugs, including an eventual rival therapy to Alexion's top-seller, into a standalone biotech. Important notice for users We bring to AstraZeneca a strong portfolio, innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics. UK: +44 203 481 5237 AstraZeneca shares fell sharply after it agreed to a $39bn (£29bn) takeover of the US rare diseases specialist Alexion, the biggest deal in its history if it goes ahead. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Evercore, Centerview Partners and Ondra, each of which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, are each acting exclusively for AstraZeneca and no one else in connection with the transaction and the matters referred to in this document and will not regard any other person as a client in relation to the matters set out in this document and will not be responsible to anyone other than AstraZeneca for providing the protections afforded to their respective clients, nor for providing advice in relation to the transaction or any other matter referred to in this document. Alexion shareholders are in line to receive $60 in cash plus 2.1243 of AstraZeneca's American depository shares (ADS). AstraZeneca has built a growing scientific presence in oncology, and in cardiovascular, renal and metabolism, and respiratory diseases, with a focus on organ protection. The capabilities of both organisations will create a company with great strengths across a range of technology platforms, with the ability to bring innovative medicines to millions of people worldwide. Freshfields Bruckhaus Deringer is acting as legal counsel. ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS IN CERTAIN JURISDICTIONS. Under the terms of the acquisition agreement, AstraZeneca has agreed that for 12 months following closing, it will provide the Alexion employees with the same level of salary as such employees had before closing, incentive compensation opportunities that are in the aggregate no less favourable than those provided before closing and substantially comparable benefits to those provided before closing. Bank of America Securities is serving as financial advisor to Alexion, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel. A webinar and conference call for investors and analysts will begin at 2:00 pm UK time today, please join 10-15 minutes prior to the scheduled start time. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH CONSENT OR OTHER FORMALITY WHICH AstraZeneca REGARDS AS UNDULY ONEROUS. More recently, Alexion launched Ultomiris (ravulizumab), a second-generation C5 monoclonal antibody with a more convenient dosing regimen. See here for a complete list of exchanges and delays. Our country sites can be located in the AZ Network. Neither Goldman Sachs International, nor Goldman Sachs Bank USA, nor any of their respective subsidiaries, holding companies, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client in connection with the transaction or any statement contained herein or otherwise. The acquisition also strengthens AstraZeneca's cash-flow generation, providing additional flexibility to reinvest in R&D and rapid debt reduction, with an ambition to increase the dividend. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the … We encourage you to read the privacy policy of every website you visit. Adrian Kemp All persons resident or located outside the United Kingdom and the United States who wish to view this area of the website must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so and should inform themselves of, and observe, any applicable legal or regulatory requirements applicable in their jurisdiction. The companies will mutually agree on two individuals from the Alexion board of directors who will join the AstraZeneca board as directors upon closing of the acquisition. These forward looking statements include all matters that are not historical facts and involve predictions. The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq exchange for each of their Alexion shares. Ondra LLP (“Ondra”) are providing advice as part of their ongoing financial advisory services. To the fullest extent permitted by applicable law, Goldman Sachs International, Goldman Sachs Bank USA and each of their respective affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this announcement or any statement contained therein. A proxy statement/prospectus or a proxy statement will be sent to Alexion's shareholders. Terms defined in the announcement of the Transaction dated 12 December 2020 shall have the same meaning when used in this notice. Speaking on an analyst call, 61-year-old Soriot said the deal should put to rest speculation he was on his way out, as he was determined to stay on board to see the strategic benefits of the transaction delivered. Veeva ID: Z4-25396Date of next review: August 2022. (iii) As at 9 December 2020 there were 1,312,660,216 AstraZeneca Ordinary Shares in issue of which all shares have voting rights attached. Despite generating billions in cash from treatments such as Soliris, one of the most expensive drugs in the world costing hundreds of thousands of dollars per patient, Alexion shares have struggled in recent years as investors have worried about competition heating up. AstraZeneca intends to establish Boston, Massachusetts, US as its headquarters for rare diseases, capitalising on talent in the greater Boston area. Alexion has pioneered complement inhibition for a broad spectrum of immune-mediated rare diseases caused by uncontrolled activation of the complement system, a vital part of the immune system. AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs.
Opfer 2117 Der Achte Fall Für Carl Mørck, Sonderdezernat Q, Hotel Engel Todtnauberg, Oldtimer Messe 2020, Uni Bonn Siegen Medizin Losverfahren, Ferienwohnung Bernkastel-kues Weingut, Altausseer See Temperatur, Schlachthof Karlsruhe Startups, Seifenopern Art Kreuzworträtsel, Sylt Lammfleisch Kaufen, Hohe Düne Warnemünde Adresse, Blumenkohl Mit Semmelbrösel Beilage,
Neue Kommentare